Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NFIA Eyes Gujarat For Investments In Pharma
Netherlands Foreign Investment Agency (NFIA) has shown interest in perusing pharma plyers from Gujrat to set up R&D facility in Netherlands, which constitutes a market of Rs 13,000
Netherlands Foreign Investment Agency (NFIA) has shown interest in perusing pharma plyers from Gujrat to set up R&D facility in Netherlands, which constitutes a market of Rs 13,000
Omeros has reported the results from the phase 1/phase 2 clinical trial of OMS302, an ophthalmologic PharmacoSurgery product candidate. OMS302 is a combination of an anti-inflammatory agent and
Amgen has announced the publication of results from two pivotal phase 3 studies investigating the safety and effectiveness of denosumab at reducing fracture risk, in The New England
Labopharm has submitted its response to the FDA’s complete response letter regarding the company’s novel formulation of the antidepressant – trazodone. As previously announced, Labopharm received a complete
Endocyte has reported the results from phase II clinical study of EC145. The single arm phase II study evaluated the therapeutic agent, EC145 and the molecular imaging agent,
Schering-Plough has sealed an agreement with Orchid Chemicals & Pharmaceuticals and Orgenus Pharma, related to the generic manufacturing of certain formulations of CLARINEX (desloratadine). The agreement marks the
Repros Therapeutics has received notification of a class action complaint against it, on 7 August 2009 and certain of its officers and directors, on behalf of shareholders who
The low-dose diet pill – Alli will be available over the counter in Taiwan. This makes the pill the first to be sold over the counter in Taiwan
Vion Pharmaceuticals has reported a net loss of $6.6m or $0.83 per share for the second quarter of 2009, a decrease when compared to a net loss of
Javelin Pharmaceuticals (Javelin) has provided top line results from a phase III randomized, multicenter, double-blind, 1:1 placebo-controlled study of Ereska (intranasal ketamine 30mg). The study assessed the safety